186 related articles for article (PubMed ID: 37410235)
1. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
Nordentoft I; Birkenkamp-Demtröder K; Dyrskjøt L
Methods Mol Biol; 2023; 2684():179-197. PubMed ID: 37410235
[TBL] [Abstract][Full Text] [Related]
2. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
[TBL] [Abstract][Full Text] [Related]
3. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
4. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
5. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.
Chalfin HJ; Glavaris SA; Gorin MA; Kates MR; Fong MH; Dong L; Matoso A; Bivalacqua TJ; Johnson MH; Pienta KJ; Hahn NM; McConkey DJ
Eur Urol Oncol; 2021 Apr; 4(2):310-314. PubMed ID: 31563523
[TBL] [Abstract][Full Text] [Related]
7. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Trullas R; Roldán FL; Rodríguez-Carunchio L; Juez L; Sureda J; Alcaraz A; Mengual L; Izquierdo L
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068899
[TBL] [Abstract][Full Text] [Related]
9. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of circulating tumor DNA in metastatic cancers.
Raei N; Safaralizadeh R; Latifi-Navid S
Expert Rev Mol Diagn; 2023; 23(12):1209-1220. PubMed ID: 37797209
[TBL] [Abstract][Full Text] [Related]
12. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
15. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
17. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
[TBL] [Abstract][Full Text] [Related]
18. Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.
Braig D; Runkel A; Eisenhardt AE; Schmid A; Zeller J; Pauli T; Lausch U; Wehrle J; Bronsert P; Jung M; Kiefer J; Boerries M; Eisenhardt SU
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142126
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
